359 related articles for article (PubMed ID: 22013531)
1. Glycosaminoglycan storage disorders: a review.
Coutinho MF; Lacerda L; Alves S
Biochem Res Int; 2012; 2012():471325. PubMed ID: 22013531
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses.
Minami K; Morimoto H; Morioka H; Imakiire A; Kinoshita M; Yamamoto R; Hirato T; Sonoda H
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233030
[TBL] [Abstract][Full Text] [Related]
3. Mucopolysaccharidosis III: Molecular basis and treatment.
Spahiu L; Behluli E; Peterlin B; Nefic H; Hadziselimovic R; Liehr T; Temaj G
Pediatr Endocrinol Diabetes Metab; 2021; 27(3):201-208. PubMed ID: 34743503
[TBL] [Abstract][Full Text] [Related]
4. Potential role of cathepsin K in the pathophysiology of mucopolysaccharidoses.
Wilson S; Brömme D
J Pediatr Rehabil Med; 2010; 3(2):139-46. PubMed ID: 21629671
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of Mucopolysaccharidoses, an Update.
Fecarotta S; Tarallo A; Damiano C; Minopoli N; Parenti G
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260444
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Manifestations of Mucopolysaccharidoses.
Tran MC; Lam JM
Pediatr Dermatol; 2016 Nov; 33(6):594-601. PubMed ID: 27601403
[TBL] [Abstract][Full Text] [Related]
7. Imaging findings of mucopolysaccharidoses: a pictorial review.
Palmucci S; Attinà G; Lanza ML; Belfiore G; Cappello G; Foti PV; Milone P; Di Bella D; Barone R; Fiumara A; Sorge G; Ettorre GC
Insights Imaging; 2013 Aug; 4(4):443-59. PubMed ID: 23645566
[TBL] [Abstract][Full Text] [Related]
8. Current and new therapies for mucopolysaccharidoses.
Penon-Portmann M; Blair DR; Harmatz P
Pediatr Neonatol; 2023 Feb; 64 Suppl 1():S10-S17. PubMed ID: 36464587
[TBL] [Abstract][Full Text] [Related]
9. Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets.
Leal AF; Benincore-Flórez E; Rintz E; Herreño-Pachón AM; Celik B; Ago Y; Alméciga-Díaz CJ; Tomatsu S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613919
[TBL] [Abstract][Full Text] [Related]
10. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation.
Opoka-Winiarska V; Jurecka A; Emeryk A; Tylki-Szymańska A
Osteoarthritis Cartilage; 2013 Dec; 21(12):1813-23. PubMed ID: 23954699
[TBL] [Abstract][Full Text] [Related]
11. Mucopolysaccharidoses Differential Diagnosis by Mass Spectrometry-Based Analysis of Urine Free Glycosaminoglycans-A Diagnostic Prediction Model.
D'Avanzo F; Zanetti A; Dardis A; Scarpa M; Volpi N; Gatto F; Tomanin R
Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979466
[TBL] [Abstract][Full Text] [Related]
12. Separation of sulfated urinary glycosaminoglycans by high-resolution electrophoresis for isotyping of mucopolysaccharidoses in Malaysia.
Nor A; Zabedah MY; Norsiah MD; Ngu LH; Suhaila AR
Malays J Pathol; 2010 Jun; 32(1):35-42. PubMed ID: 20614724
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and molecular analysis of mucopolysaccharidoses in Turkey.
Emre S; Terzioğlu M; Coşkun T; Tokath A; Ozalp I; Müller V; Hopwood J
Turk J Pediatr; 2002; 44(1):13-7. PubMed ID: 11858372
[TBL] [Abstract][Full Text] [Related]
14. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
[TBL] [Abstract][Full Text] [Related]
15. Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses.
Cotugno G; Tessitore A; Capalbo A; Annunziata P; Strisciuglio C; Faella A; Aurilio M; Di Tommaso M; Russo F; Mancini A; De Leonibus E; Aloj L; Auricchio A
Hum Gene Ther; 2010 May; 21(5):555-69. PubMed ID: 20021231
[TBL] [Abstract][Full Text] [Related]
16. Craniovertebral junction pathological features and their management in the mucopolysaccharidoses.
Sganzerla EP; Giussani C; Grimaldi M; Parini R; Ingelmo P; Trezza A; Visocchi M
Adv Tech Stand Neurosurg; 2014; 40():313-31. PubMed ID: 24265052
[TBL] [Abstract][Full Text] [Related]
17. Management of otolaryngological manifestations in mucopolysaccharidoses: our experience.
Mesolella M; Cimmino M; Cantone E; Marino A; Cozzolino M; Della Casa R; Parenti G; Iengo M
Acta Otorhinolaryngol Ital; 2013 Aug; 33(4):267-72. PubMed ID: 24043915
[TBL] [Abstract][Full Text] [Related]
18. Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses.
Baydakova G; Ilyushkina A; Gaffke L; Pierzynowska K; Bychkov I; Ługowska A; Wegrzyn G; Tylki-Szymanska A; Zakharova E
Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32183018
[TBL] [Abstract][Full Text] [Related]
19. From bedside to cell biology: a century of history on lysosomal dysfunction.
Coutinho MF; Matos L; Alves S
Gene; 2015 Jan; 555(1):50-8. PubMed ID: 25275857
[TBL] [Abstract][Full Text] [Related]
20. Mucopolysaccharidoses.
Cimaz R; La Torre F
Curr Rheumatol Rep; 2014 Jan; 16(1):389. PubMed ID: 24264718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
